

When Can Elimination of SARS-CoV-2 Infection be Assumed? Simulation Modelling in a Case Study Island Nation

Nick Wilson^{1,2}, Matthew Parry,³ Ayesha J Verrall⁴, Michael G Baker², Markus Schwehm⁵, Martin Eichner^{6,7}

¹ BODE³ Programme, University of Otago Wellington, New Zealand

² HEIRU, University of Otago Wellington, New Zealand

³ Department of Mathematics & Statistics, University of Otago, Dunedin, New Zealand

⁴ Department of Pathology and Molecular Medicine, University of Otago Wellington, New Zealand

⁵ ExploSYS GmbH, Leinfelden, Germany

⁶ University of Tübingen, Germany

⁷ Epimos GmbH, Germany

Abstract

Aims: We aimed to determine the length of time from the last detected case of SARS-CoV-2 infection before elimination can be assumed at a country level in an island nation.

Methods: A stochastic version of the SEIR model CovidSIM v1.1 designed specifically for COVID-19 was utilised. It was populated with data for the case study island nation of New Zealand (NZ) along with relevant parameters sourced from the NZ and international literature. This included a testing level for symptomatic cases of 7,800 tests per million people per week.

Results: It was estimated to take between 27 and 33 days of no new detected cases for there to be a 95% probability of epidemic extinction. This was for effective reproduction numbers (R_e) in the range of 0.50 to 1.0, which encompass such controls as case isolation (the shorter durations relate to low R_e values). For a 99% probability of epidemic extinction, the equivalent time period was 37 to 44 days. In scenarios with lower levels of symptomatic cases seeking medical attention and lower levels of testing, the time period was up to 53 to 91 days (95% level).

Conclusions: In the context of a high level of testing, a period of around one month of no new notified cases of COVID-19 would give 95% certainty that elimination of SARS-CoV-2 transmission had been achieved.

Introduction

Some nations are attempting to eliminate the SARS-CoV-2 pandemic virus as in the case of New Zealand¹ and for Australia this has been articulated as a potential option.² It might also be the goal for the island jurisdiction of Taiwan and for South Korea, which has well controlled land borders (though neither of these places appears to have actually specified this goal).

Once a nation can declare itself having achieved elimination status it can potentially phase out restrictive disease control measures within the country, while maintaining tight border controls with quarantine for incoming travellers. It could also permit quarantine-free travel with other COVID-19 free nations, as envisaged by the Prime Ministers of Australia and New Zealand in terms of a trans-Tasman “bubble”.³ Similarly, the leaders of Austria, Greece, Israel, Norway, Denmark, the Czech Republic, Singapore, Australia and New Zealand “agreed that as each begins to ease restrictions they could capitalise on low infection rates by creating tourism safe zones”.⁴

We selected New Zealand as a case study island nation as it has an elimination goal,¹ has good border controls and is making steady progress towards elimination with occasional days in May 2020 with no new cases reported.⁵ Some work has already been done on the elimination topic in New Zealand, with a modelling group⁶ reporting that a “90 day period at Level 4 [intensive lock-down restrictions] leads to containment to very low levels by the end of the 90 day period”. “This scenario leads to elimination in approximately 50% of stochastic realisations”. Another study⁷ estimated the probability that regions within New Zealand might have achieved elimination, with the District Health Board region with the highest number of days free of notified cases (Wairarapa at 16 days as of 18 April 2020) having a 92% probability of having eliminated the pandemic virus. However, none of this work has defined time periods for differing levels of probability for elimination being achieved at a whole country level. Estimating these periods was therefore the aim of this simulation study.

Methods

To run “time to elimination” analyses for New Zealand, we used a stochastic SEIR type model with key compartments for: susceptible [S], exposed [E], infected [I], and recovered/removed [R]. The model is a stochastic version of CovidSIM which was developed specifically for COVID-19 (<http://covidsim.eu>; version 1.1). Work has been published from previous versions of this model,^{8,9} but in the Appendix we provide updated parameters and differential equations for version 1.1. A similar simulation approach was taken previously for a poliomyelitis elimination study.¹⁰ The stochastic model was built in Pascal and 10,000 simulations were run for each set of parameter values.

The parameters were based on available publications and best estimates used in the published modelling work on COVID-19 (as known to us on 13 May 2020). Key components were: a starting position of 10 infected cases, the assumption of effective border control with no new imported cases, 80% of infected COVID-19 cases being symptomatic, 39.5% of cases seeking medical consultation in primary care settings, and 4% of symptomatic cases being hospitalised (see Table A1 in the Appendix for the full set of parameters used). The level of testing of symptomatic cases in primary care and for respiratory cases being tested when hospitalised (both at 95% coverage with test sensitivity of 89%¹¹), was as per a fairly optimal surveillance system conducting 7,800 tests per million people per week (slightly less than the level in New Zealand as per mid-May 2020 at 8,190 tests per million people per week¹²). Identified cases were transferred to supervised isolation which was assumed to be 95% effective. We considered different levels of transmission with the effective

reproduction number (R_e) of SARS-CoV-2 to be 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0 (with extinction still occurring in the last case [$R_e = 1.0$] due to accumulation of immune individuals after infection). These levels of R_e were assumed to represent the summated total of pandemic-related physical distancing (voluntary and mandated), travel restrictions, hygiene behaviours, mask use, voluntary staying at home when unwell, and contact tracing resulting in quarantine of contacts.

In each stochastic simulation, the delay since the last detected cases was stored on a daily basis together with the information as to whether infection was still ongoing or was extinguished. The probability that extinction had occurred if no cases have been reported for a given number of days was calculated by dividing the number of such delays during extinction by the total number of such delays (ie, with ongoing transmission or with extinction). Other scenarios considered the impact of higher starting numbers of infected cases, and lower levels of attendance for medical consultations in primary care and also for the level of testing.

Results

It was estimated to take between 27 and 33 days of no new detected cases for there to be 95% probability of epidemic extinction for effective reproduction numbers (R_e) in the range of 0.5 to 1.0, combined with effective case isolation (Table 1; the shorter durations relate to low R_e values as depicted in Figure 1). This range was 37 to 44 days (around 5 to 6 weeks) for the 99% probability level. In scenarios with lower levels of symptomatic cases seeking medical attention and lower levels of testing, the time period was up to 53 to 91 days (second scenario in Table 1; Figure 2; for the 95% level of probability). Starting the simulations with 100 or 1000 initially infected cases instead of 10, made no meaningful difference (Figure 2). This was expected because while there are 1000 or 100 infected individuals in the population, the frequency of very short case-free intervals of up to a few days at most are very frequent whereas long case free intervals of weeks are virtually impossible. Only after the number of cases has dropped to very low numbers, case-free periods of weeks may occasionally occur despite ongoing transmission. Also only for such long case-free periods is there an ambiguity whether extinction has occurred or not, whereas nobody would assume that extinction has occurred if no cases have been reported for two or three days.

Table 1: Probability level of SARS-CoV-2 elimination by number of days since the last detected case of COVID-19 (starting with 10 infectious cases for each value of R_e in the range of: 0.5 to 1.0; using 10,000 simulations per parameter set).

Base case and scenarios	50% probability	95% probability
Base case analysis: 39.5% of symptomatic cases seek medical attention in primary care [Flutracking data for NZ] where 95% of them are tested	12 to 15 days	27 to 33 days
Scenario 1: 30% seek attention, 60% of them are tested	17 to 24 days	38 to 51 days
Scenario 2: 20% seek attention, 30% of them are tested	24 to 42 days	53 to 91 days

Figure 1: Probability that pandemic virus extinction has occurred according to different R_e values. The chart shows extinction probabilities if no new COVID-19 cases have been reported for a given number of days (10,000 simulations starting with 10 infectious cases for each value of R_e). The curves from left to right relate to $R_e = 0.5, 0.6, 0.7, 0.8, 0.9, 1.0$, respectively.





Figure 2: Probability that pandemic virus extinction has occurred according to different numbers of initial cases and testing proportions. The chart shows extinction probabilities if no new COVID-19 cases have been detected for a given number of days (effective reproduction number $R_e=0.8$; 10,000 simulations each scenario). The three black curves on the left (nearly undistinguishable) give the results obtained when starting the simulations with 10 (solid), 100 (dotted) or 1,000 (dashed) infections, respectively. The dark grey curve shows the result when only 30% of COVID-19 patients seek medical attention and only 60% of them are tested (Scenario 1). The light grey curve on the right shows the result when only 20% seek medical attention and only 30% of them are tested (Scenario 2).



Discussion

These simulations suggest that with an effective surveillance system (high levels of testing symptomatic cases with cough and fever and testing of respiratory cases being hospitalised), it is possible to develop high assurance that an elimination goal has been achieved in around four to five weeks of no cases being detected (Figure 1). Of course this modelling assumes that R_e values are being successfully suppressed (at $R_e \leq 1.0$), which may be feasible if there are both rigorous public health control measures (contact tracing, case isolation etc) and people maintain some levels of behaviour change in the peri-elimination period (hand and respiratory hygiene, mask use, working from home where feasible, staying home when unwell etc).

The time period for no new cases we have identified of four to five weeks is similar to a provisional “28 days since the onset date of the last known infection” that has been suggested for New Zealand previously.¹³ This is also the span of two maximal incubation periods (14 days, which is being used for determining the length of quarantine for incoming travellers in New Zealand). A 28 day period for elimination has also been proposed for the Australian setting.² Nevertheless, it is possible that the 99% level of probability provides a better safety margin (ie, the 37 to 44 day period we have estimated). This would be more appropriate if there are uncertainties with the distribution of testing by geographical region and socio-demographic group. It might also be considered more appropriate by policy makers wanting to reduce international travel restrictions between COVID-19 free nations (see *Introduction*).

A limitation of our work is that we didn’t perform scenario analyses that captured differing performance of the contact tracing system – instead we assumed that effective routine contact tracing was part of the low R_e values. A more sophisticated model (eg, an agent based SEIR model) would be needed to separate out the effect of contact tracing. Another limitation was that we didn’t consider extreme scenarios such as residual transmission amongst groups of school children where infection is more likely to be asymptomatic or only mildly symptomatic (ie, this could result in further delays in detection).

Conclusion

In the context of a high level of testing, a period of around one month of no new notified cases of COVID-19 would give 95% certainty that elimination of SARS-CoV-2 transmission had been achieved.

Competing interests: The authors have no competing interests.

Acknowledgements: Dr Schwehm is supported by the University of Tübingen and the IMAAC-NEXT Association. Professor Wilson is supported by the New Zealand Health Research Council and Ministry of Business Innovation and Employment (MBIE) funding of the BODE3 Programme.

Appendix: Mathematical description of the CovidSIM model (version 1.1) and model parameters

The stochastic simulations are based on the following differential equations:

Model dynamics

Number of susceptible individuals

$$\frac{dS}{dt} = -\lambda S$$

Number of individuals in the latent period

$$\frac{dE_1}{dt} = \lambda S - \varepsilon E_1$$

$$\frac{dE_k}{dt} = \varepsilon E_{k-1} - \varepsilon E_k \quad (2 \leq k \leq n_E)$$

Number of individuals in the prodromal period

$$\frac{dP_1}{dt} = \varepsilon E_{n_E} - \varphi P_1$$

$$\frac{dP_k}{dt} = \varphi P_{k-1} - \varphi P_k \quad (2 \leq k \leq n_P)$$

Number of individuals in the early infectious period

$$\frac{dI_1}{dt} = \varphi P_{n_P} - \gamma I_1$$

$$\frac{dI_k}{dt} = \gamma I_{k-1} - \gamma I_k \quad (2 \leq k \leq n_I)$$

Number of individuals in the late infectious period

$$\frac{dL_1}{dt} = \gamma I_{n_I} - \delta L_1$$

$$\frac{dL_k}{dt} = \delta L_{k-1} - \delta L_k \quad (2 \leq k \leq 3)$$

$$\frac{dL_A}{dt} = \delta(1 - f_{Iso})L_3 - \delta L_A$$

$$\frac{dL_k}{dt} = \delta L_{k-1} - \delta L_k \quad (5 \leq k \leq n_L)$$

Number of isolated individuals

$$\frac{dX_A}{dt} = \delta f_{Iso} L_3 - \delta X_A$$

$$\frac{dX_k}{dt} = \delta X_{k-1} - \delta X_k \quad (5 \leq k \leq n_L)$$

Derived variables

Total number in latent period

$$E_{Sum}(t) = \sum_{k=1}^{n_E} E_k(t)$$

Total number in prodromal period

$$P_{Sum}(t) = \sum_{k=1}^{n_P} P_k(t)$$

Total number in early infectious period

$$I_{Sum}(t) = \sum_{k=1}^{n_I} I_k(t)$$

Total number in late infectious period $L_{Sum}(t) = \sum_{k=1}^{n_L} L_k(t)$

Total number of isolated individuals $X_{Sum}(t) = \sum_{k=4}^{n_L} X_k(t)$

Contact rate and force of infection

Contact rate $\beta = \frac{R_e}{c_P D_P + D_I + c_L D_L \left(\frac{3}{n_L} + \frac{n_L - 3}{n_L} (1 - f_{Iso} P_{Iso}) \right)}$

Force of infection $\lambda(t) = \frac{\beta}{N} (c_P P_{Sum}(t) + I_{Sum}(t) + c_L (L_{Sum}(t) + (1 - p_{Iso}) X_{Sum}(t)))$

Stochastic treatment of the differential equations

The kind of epidemiologic events and the duration between two consecutive events are calculated using random numbers. The simulations start with a susceptible population with a given number of infected individuals (“index cases”). The individual infection stages of these index cases are picked at random, taking into consideration the different lengths of the latent, prodromal, early and late infectious period. In each simulation, the sum of all the rates that change the current state of the system is calculated as

$$\xi = \lambda S + \varepsilon E_{Sum} + \varphi P_{Sum} + \gamma I_{Sum} + \delta (L_{Sum} + X_{Sim})$$

A uniformly distributed random number $r_1 \in [0, \xi]$ is then chosen, and the time $\Delta t = -\ln(r_1) / \xi$ after which the next event occurs is calculated. All transition rates are arranged in an arbitrary order, and cumulative rates are calculated by adding their individual rates. A new uniformly distributed random number $r_2 \in [0, \xi]$ is chosen, and the first transition in the order whose cumulative rate is larger than r_2 is performed. If, for example, the event is an infection, one individual is removed from the group of susceptible individuals and added to the group of latent individuals of stage 1. If a transition is scheduled to take place to an individual in stage L_3 , a third random number is calculated to determine whether the case is diagnosed and isolated or whether the case progresses to L_4 . New rates are calculated after each step, and the procedure is repeated. A more detailed description of the transformation of differential equation models to stochastic models can be found in Gillespie (1976).¹⁴

Parameters

N	Population size
λ	Force of infection
R_e	Effective reproduction number
β	Effective contact rate
D_E	Average duration of the latent period
n_E	Number of stages for the latent period
ε	Stage transition rate for the latent period ($\varepsilon = n_E / D_E$)
D_P	Average duration of the prodromal period
n_P	Number of stages for the prodromal period
φ	Stage transition rate for the prodromal period ($\varphi = n_P / D_P$)
c_P	Contagiousness in the prodromal period (relative to the contagiousness in the early infectious period)
D_I	Average duration of the early infectious period
n_I	Number of stages for the early infectious period
γ	Stage transition rate for the early infectious period ($\gamma = n_I / D_I$)
D_L	Average duration of the late infectious period
n_L	Number of stages for the late infectious period
δ	Stage transition rate for the late infectious period ($\delta = n_L / D_L$)
c_L	Contagiousness in the late infectious period (relative to the contagiousness in the early infectious period)
f_{Sick}	Fraction of individuals in the (early and late) “infectious period” who have symptoms (i.e. who are sick)
$f_{Consult}$	Fraction of sick cases who seek medical help
f_{Hosp}	Fraction of sick cases who are hospitalized
f_{Test}	Tested fraction of cases who seek medical help or who are hospitalized
s_{Test}	Sensitivity of the test

$f_{Iso} = f_{Sick} (f_{Consult} + f_{Hosp}) f_{Test} S_{Test}$ Fraction of infected individuals who are isolated due to a positive test result

p_{Iso} Fraction of contacts which are prevented for isolated cases

Table A1: Input parameters used for modelling the potential spread of the COVID-19 pandemic with the stochastic version of CovidSIM (v1.1) with New Zealand as a case study

Parameter	Value/s used	Further details for parameter inputs into the modelling
Population size	4,951,500	We used the estimated NZ population as per December 2019 (ie, 4,951,500 ¹⁵).
Initial number of infected cases	10 (varied in scenario analyses)	The initial status of these cases was randomly selected taking into consideration the durations of the different stages.
Infections that lead to sickness	80%	We used the same proportion (80%) of symptomatic cases as per a Chinese study, ¹⁶ and as per an Australian modelling study. ¹⁷ This value is higher than the 57% value found in an Icelandic study ¹⁸ but this study did not involve long-term follow-up of the asymptomatic cases (ie, some of the asymptomatic cases might subsequently have developed symptoms). But it is also lower than that found in another Chinese study (at 94% symptomatic). ¹⁹
Sick people who seek medical attention in primary care	39.5%	We used the result from the NZ Flutracking surveillance system for people with “fever and cough” in the weekly surveys who report seeking medical attention for these symptoms. ²⁰ This is very similar to international estimates for people with influenza who seeking medical attention at 40% eg, as used in other modelling. ⁸
Sick people need hospitalisation	4%	At the time of writing on 3 May 2020, there were 8 people hospitalised in NZ with COVID-19 (out of a total of 201 actively infected cases, ie, 4.0% ²¹). Of note is that modellers in the United Kingdom (UK) have used 4.4% (of all infected cases), ²² and for modelling in the United States 3%, 5% and 12% have been proposed. ²³ The length of hospitalisation was assumed to be 10 days which is similar to other modelling work eg, 10.4 days for the UK. ²²
Latency period	4 days	We used an average duration of 4 days as per Read et al, ²⁴ with a standard deviation (SD) of 25% (1 day) (calculated using 16 stages; Erlang distribution). This is similar to the estimate in a Chinese study which reported a median latent period of 3.69 days. ²⁵
Prodromal period	1 day	There is as yet insufficient data on this for COVID-19, so we used an assumed value for influenza (SD = 25%; 0.25 days), Erlang distribution).
Symptomatic period	10 days (split into 2 periods of 5 days each)	The WHO-China Joint Mission report stated that “the median time from onset to clinical recovery for mild cases is approximately 2 weeks and is 3-6 weeks for patients with severe or critical disease”. ²⁶ But given that mild cases may have been missed in this particular assessment, we used a slightly shorter total time period of 10 days (SD = 25%; 2.5 days), Erlang distribution).
Contagiousness and control measures		
Effective reproduction number (Re)	0.5, 0.6, 0.7, 0.8, 0.9, 1.0	In the peri-elimination phase of pandemic control, we assumed Re values in this range to ensure extinction occurred in the simulations. Extinction still occurred when simulations started with Re = 1.0 due to the accumulation of immune individuals in the course of the simulations, gradually reducing Re(t) to values slightly below 1. These levels of Re were assumed to represent the summated total of pandemic-related physical distancing (voluntary and mandated), travel restrictions, hygiene behaviours, mask

Parameter	Value/s used	Further details for parameter inputs into the modelling
		use, voluntary staying at home when unwell, and contact tracing resulting in quarantine of contacts.
Relative contagiousness in the prodromal period	50%	There is uncertainty around this value but we used the same estimate as in recent UK modelling. ²² This has biological plausibility as while there is similarity in viral loads between asymptomatic and symptomatic COVID-19 patients, ²⁷ it would be expected that those who are fully symptomatic (with a cough etc.) would be more likely to transmit infection. Of note is an estimate from the Diamond Princess cruise ship outbreak, that 17.9% of COVID-19 infections were from asymptomatic individuals (95% credible interval 15.5-20.2%). ²⁸ But it is unclear how generalisable this finding is given the crowded cruise ship conditions and the typically elderly nature of the passengers.
Contagiousness during the two symptomatic periods	100% and 50%	In the first five days of symptoms, cases were considered to be fully contagious. In the second five-day period, this was assumed to be at 50%. The latter figure is highly uncertain, but is broadly consistent with one study on changing viral load. ²⁹
Prevented fraction of contacts for isolated cases	95% effectiveness	This value is not precisely known for NZ but isolation of known cases is thought to be fairly well supervised and there has been high public support for pandemic control measures which may improve adherence to such constraints.
Provision of testing and test sensitivity assumed		
Background hospital admissions for respiratory conditions in NZ	234 admissions per day	Using 85,439 respiratory disease admissions to NZ public hospitals in the year 2016/2017 (for all Chapter X ICD10 codes: J00 to J99). ³⁰
Background medical consultations in primary care for respiratory conditions in NZ	5,640 consultations per day	Data from the NZ arm of the Flutracking surveillance system was used. This indicates that approximately 3% of respondents in the period from April to October report “fever and cough” in the weekly surveys. ²⁰ Of these 39.5% report seeking medical attention for their symptoms. However, we assumed a lower annual rate of 2% to account for the period outside of the influenza season (eg, Flutracking reporting is closer to 1% for weekly “fever and cough” at the start of May when the surveillance system begins for the year). In the NZ population of 5 million this would suggest 14,300 new cases developing “cough and fever” per day of whom 5640 would be expected to seek medical attention.
Coverage in patients with respiratory symptoms who seek medical attention in primary care	95% coverage	These coverage values were further adjusted for the test sensitivity of 89% (see below). With 95% coverage and 89% test sensitivity, 84.55% of cases would be detected. Combined with hospital testing (see below) this resulted in a testing level of 7,800 tests per million per week (Submitted manuscript).
Coverage in hospitalised patients with respiratory symptoms	95% coverage	As above.
PCR test sensitivity	89%	A meta-analysis has reported this as 89% (95%CI: 81 to 94%). ¹¹ This sensitivity is not ideal as while infection can be in the lungs, the sampling is from the nasopharynx, which may contain lower levels of virus at some stages of infection. Specificity is close to 100% for the PCR test.
Lag times (for health sector interaction and testing delays)		
Delay from symptom onset	5 days plus 1 day for the	There is a delay between symptom onset and the performance of the test for SARS-CoV-2. For the first part of the delay we considered a study in

Parameter	Value/s used	Further details for parameter inputs into the modelling
until a test has been performed and the result has become available	testing delay	Beijing, China, which reported the interval time from between illness onset and seeing a doctor was 4.5 days. ³¹ Another Chinese study of 710 patients with pneumonia ³² reported that those dying had a median duration from onset of symptoms to radiological confirmation of pneumonia of 5 (IQR: 3–7) days. For the testing delay we noted that the aim in NZ is to obtain the result of the tests in under 24-hours regardless of the primary care or hospital setting. But this may not always be the case for rural and small town settings. In our simulations, test results were available on average 5.94 days after symptom onset (SD: 1.36 days).

References

1. Baker M, Kvalsvig A, Verrall A, Telfar-Barnard L, Wilson N. New Zealand's elimination strategy for the COVID-19 pandemic and what is required to make it work. *N Z Med J* 2020;133(1512):10-14.
2. Group of Eight Australia. COVID-19 Roadmap to Recovery: A Report for the Nation. The Group of Eight Ltd. 2020. <https://go8.edu.au/research/roadmap-to-recovery>
3. Radio New Zealand. Trans-Tasman bubble: Jacinda Ardern gives details of Australian Cabinet meeting. Radio NZ 2020;(5 May). <https://www.rnz.co.nz/news/political/415869/trans-tasman-bubble-jacinda-ardern-gives-details-of-australian-cabinet-meeting>.
4. Graham-Harrison E, Smith H. What is the future for travel and migration in age of Covid-19? *Guardian* 2020;(12 May). <https://www.theguardian.com/world/2020/may/12/what-is-the-future-for-travel-and-immigration-in-age-of-covid-19>.
5. Ministry of Health. No new cases. (Media release). NZ Ministry of Health 2020;(4 May). <https://www.health.govt.nz/news-media/media-releases/no-new-cases>.
6. Plank M, Binny R, Hendy S, Lustig A, James A, Steyn N. A stochastic model for COVID-19 spread and the effects of Alert Level 4 in Aotearoa New Zealand. medRxiv 2020;(11 April) <https://doi.org/10.1101/2020.04.08.20058743doi>.
7. Bogacz R. Estimating the probability of New Zealand regions being free from COVID-19 using a stochastic SEIR model. medRxiv 2020;(21 April). <https://doi.org/10.1101/2020.04.20.20073304doi>.
8. Wilson N, Telfar Barnard L, Kvalsig A, Verrall A, Baker M, Schwehm M. Modelling the potential health impact of the COVID-19 pandemic on a hypothetical European country. medRxiv 2020;(23 March). <https://medrxiv.org/cgi/content/short/2020.03.20.20039776v1>.
9. Wilson N, Telfar Barnard L, Kvalsvig A, Baker M. Potential health impacts from the COVID-19 pandemic for New Zealand if eradication fails: Report to the NZ Ministry of Health. Wellington: University of Otago Wellington, 2020. https://www.health.govt.nz/system/files/documents/publications/report_for_moh_-_covid-19_pandemic_nz_final.pdf.
10. Eichner M, Dietz K. Eradication of poliomyelitis: when can one be sure that polio virus transmission has been terminated? *Am J Epidemiol* 1996;143:816-22.
11. Kim H, Hong H, Yoon SH. Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis. *Radiology* 2020:201343.
12. Ministry of Health. Lab testing and capacity. New Zealand Ministry of Health. [Data on 7-day rolling average up to 14 May 2020]. <https://www.health.govt.nz/our-work/diseases-and->

- [conditions/covid-19-novel-coronavirus/covid-19-current-situation/covid-19-current-cases#lab](#).
13. Baker M, Wilson N, Hendy S, Skegg D. The need for a robust scientific definition for the elimination of COVID-19 from New Zealand. *Public Health Expert Blog* 2020;(5 May). <https://blogs.otago.ac.nz/pubhealthexpert/2020/05/05/the-need-for-a-robust-scientific-definition-for-the-elimination-of-covid-19-from-new-zealand/>.
 14. Gillespie D. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. *J Comput Phys* 1976;22:403-34.
 15. Statistics New Zealand. Population (December 2019). Statistics New Zealand. <https://www.stats.govt.nz/topics/population> <https://www.stats.govt.nz/topics/population>.
 16. Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020.
 17. Lokuge K, Banks E, Davies S, Roberts L, Street T, O'Donovan D, et al. Exit strategies: optimising feasible surveillance for detection, elimination and ongoing prevention of COVID-19 community transmission. medRxiv 2020;(23 April). doi: <https://doi.org/10.1101/2020.04.19.20071217>.
 18. Gudbjartsson DF, Helgason A, Jonsson H, Magnusson OT, Melsted P, Norddahl GL, et al. Spread of SARS-CoV-2 in the Icelandic Population. *N Engl J Med* 2020.
 19. Luo L, Dan L, Xin-long L, Xian-bo W, Qin-long J, Jia-zhen Z, et al. Modes of contact and risk of transmission in COVID-19 among close contacts. medRxiv 2020;(24 March). <https://www.medrxiv.org/content/10.1101/2020.03.24.20042606v1>.
 20. Flutracking. NZ participant annual report 2018. <https://info.flutracking.net/wp-content/uploads/2020/02/NZ-participant-annual-report-2018.pdf>
 21. Ministry of Health. COVID-19 - current cases. [Data as of 7 April, 2020]. <https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-current-situation/covid-19-current-cases>.
 22. Ferguson N, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College 2020;(16 March):1-20.
 23. Fink S. Worst-case estimates for U.S. coronavirus deaths. New York Times 2020;(Updated 14 March). <https://www.nytimes.com/2020/03/13/us/coronavirus-deaths-estimate.html>.
 24. Read J, Bridgen J, Cummings D, Ho A, Jewell C. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. medRxiv 2020. doi: <https://doi.org/10.1101/2020.01.23.20018549>.
 25. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* 2020.
 26. WHO-China Joint Mission. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020;(16-24 February). <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>.
 27. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *N Engl J Med* 2020.
 28. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill* 2020;25:pii=2000180. <https://doi.org/10.2807/1560-7917>.
 29. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020.

30. Ministry of Health. Publicly funded hospital discharges – 1 July 2016 to 30 June 2017. <https://www.health.govt.nz/publication/publicly-funded-hospital-discharges-1-july-2016-30-june-2017>.
31. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. *J Infect* 2020;80:401-06.
32. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020;Published Online (21 February). [https://doi.org/10.1016/S2213-2600\(20\)30079-5](https://doi.org/10.1016/S2213-2600(20)30079-5).